White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis

Journal of Cerebral Blood Flow and Metabolism

Volumn 32, Issue 3, 2012, Pages 413-424

  Cambron, Melissa ^a   D'Haeseleer, Miguel ^a   Laureys, Guy ^a   Clinckers, Ralph ^b   Debruyne, Jan ^a   De Keyser, Jacques ^a,c  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

astrocytes; axonal degeneration; energy metabolism; multiple sclerosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA 2 ADRENERGIC RECEPTOR; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTIC ACID; N ACETYLASPARTIC ACID; NITRIC OXIDE; POTASSIUM; SODIUM;

ASTROCYTE; CELL DAMAGE; ENERGY METABOLISM; GLYCOGENOLYSIS; HUMAN; MITOCHONDRIAL RESPIRATION; MULTIPLE SCLEROSIS; MYELINATION; NERVE FIBER DEGENERATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; WHITE MATTER;

ASTROCYTES; AXONS; BRAIN; ENERGY METABOLISM; GLUTAMIC ACID; HUMANS; MITOCHONDRIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; PHOSPHOCREATINE;

EID: 84857787751     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2011.193     Document Type: Review

References (114)

1. Aboul-Enein F, Krssak M, Hoftberger R, Prayer D, Kristoferitsch W (2010) Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla. PLoS One 5:e11625
2. Aksenov M, Aksenova M, Butterfield DA, Markesbery WR (2000) Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem 74:2520-7
3. Aksenova MV, Aksenov MY, Payne RM, Trojanowski JQ, Schmidt ML, Carney JM, Butterfield DA, Markesbery WR (1999) Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dement Geriatr Cogn Disord 10:158-65
4. Alix JJ, Domingues AM (2011) White matter synapses: form, function, and dysfunction. Neurology 76:397-404
5. Allaman I, Fiumelli H, Magistretti PJ, Martin JL (2011) Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology 216:75-84
6. Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D'Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42:1001-6
7. Anderson CM, Swanson RA (2000) Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32:1-14
8. Ando S, Tanaka Y, Toyoda Y, Kon K (2003) Turnover of myelin lipids in aging brain. Neurochem Res 28:5-13
9. Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, Matthews PM, Hauser SL, Oksenberg JR, Pelletier D (2010) Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 133:2603-11
10. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB (1996) Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 7:1397-400
11. Benedetti B, Rovaris M, Rocca MA, Caputo D, Zaffaroni M, Capra R, Bertolotto A, Martinelli V, Comi G, Filippi M (2009) In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler 15:789-94
12. Bergers E, Bot JC, De Groot CJ, Polman CH, Lycklama a Nijeholt GJ, Castelijns JA, van der Valk P, Barkhof F (2002) Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 59:1766-71
13. Broholm H, Andersen B, Wanscher B, Frederiksen JL, Rubin I, Pakkenberg B, Larsson HB, Lauritzen M (2004) Nitric oxide synthase expression and enzymatic activity in multiple sclerosis. Acta Neurol Scand 109:261-9
14. Brookes N (1992) Regulation of the glutamine content of astrocytes by cAMP and hydrocortisone: effect of pH. Neurosci Lett 147:139-42
15. Brosnan JT, Brosnan ME (2007) Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu Rev Nutr 27:241-61
16. Brown AM, Baltan Tekkok S, Ransom BR (2004) Energy transfer from astrocytes to axons: the role of CNS glycogen. Neurochem Int 45:529-36
17. Brown AM, Ransom BR (2007) Astrocyte glycogen and brain energy metabolism. Glia 55:1263-71
18. Cader S, Johansen-Berg H, Wylezinska M, Palace J, Behrens TE, Smith S, Matthews PM (2007) Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis. Neuroimage 36:19-27
19. Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, Miller DH (2002) Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125:2342-52
20. Chiti Z, Teschemacher AG (2007) Exocytosis of norepinephrine at axon varicosities and neuronal cell bodies in the rat brain. FASEB J 21:2540-50
21. Ciccarelli O, Altmann DR, McLean MA, Wheeler-Kingshott CA,Wimpey K, Miller DH, Thompson AJ (2010a) Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology 74:721-7
22. Ciccarelli O, Toosy AT, De Stefano N, Wheeler-Kingshott CA, Miller DH, Thompson AJ (2010b) Assessing neuronal metabolism in vivo by modeling imaging measures. J Neurosci 30:15030-3
23. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502-17
24. Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606-16
25. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65: 1-105
26. Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH (1997) 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 63:736-42
27. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117(Part 1):49-58
28. De Keyser J, Mostert JP, Koch MW (2008) Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci 267:3-16
29. De Keyser J, Wilczak N, Leta R, Streetland C (1999) Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 53:1628-33
30. De Keyser J, Zeinstra E, Wilczak N (2004) Astrocytic beta2-adrenergic receptors and multiple sclerosis. Neurobiol Dis 15:331-9
31. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL (1998) Axonal damage correlates with disability in patients with relapsingremitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121 (Part 8):1469-77
32. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65-70
33. De Stefano N, Narayanan S, Francis SJ, Smith S, Mortilla M, Tartaglia MC, Bartolozzi ML, Guidi L, Federico A, Arnold DL (2002) Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 59:1565-71
34. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM (2006) The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129:1507-16
35. Domercq M, Etxebarria E, Perez-Samartin A, Matute C (2005) Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia 52:36-46
36. Domercq M, Matute C (1999) Expression of glutamate transporters in the adult bovine corpus callosum. Brain Res Mol Brain Res 67:296-302
37. Dutta R, Chang A, Doud MK, Kidd GJ, Ribaudo MV, Young EA, Fox RJ, Staugaitis SM, Trapp BD (2011) Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 69:445-54
38. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478-89
39. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 47:391-5
40. Fan TW, Yuan P, Lane AN, Higashi RM, Wang Y, Hamidi AB, Zhou R, Guitart X, Chen G, Manji HK, Kaddurah-Daouk R (2010) Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics 6:165-79
41. Feinstein DL (1998) Suppression of astroglial nitric oxide synthase expression by norepinephrine results from decreased NOS-2 promoter activity. J Neurochem 70:1484-96
42. Feinstein DL, Galea E, Reis DJ (1993) Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J Neurochem 60:1945-8
43. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120(Part 3):393-9
44. Fonseca LL, Monteiro MA, Alves PM, Carrondo MJ, Santos H (2005) Cultures of rat astrocytes challenged with a steady supply of glutamate: new model to study flux distribution in the glutamate-glutamine cycle. Glia 51:286-96
45. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175-89
46. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, Antel JP, Wolfson C, Arnold DL (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121 (Part 1):103-13
47. Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR (2009) Rate of brain atrophy in benign versus early multiple sclerosis. Arch Neurol 66:234-7
48. Geeraedts F, Wilczak N, van Binnendijk R, De Keyser J (2004) Search for morbillivirus proteins in multiple sclerosis brain tissue. Neuroreport 15:27-32
49. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13:554-73
50. Gunter TE, Yule DI, Gunter KK, Eliseev RA, Salter JD (2004) Calcium and mitochondria. FEBS Lett 567:96-102
51. Hassel B (2001) Pyruvate carboxylation in neurons. J Neurosci Res 66:755-62
52. Hertz L, Gibbs ME (2009) What learning in day-old chickens can teach a neurochemist: focus on astrocyte metabolism. J Neurochem 109(Suppl 1):10-6
53. Hertz L, Peng L, Dienel GA (2007) Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. J Cereb Blood Flow Metab 27:219-49
54. Husted CA, Goodin DS, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, Fein G, Matson GB, Weiner MW (1994) Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 36:157-65
55. Irvine KA, Blakemore WF (2008) Remyelination protects axons from demyelination-associated axon degeneration. Brain 131:1464-77
56. Karadottir R, Attwell D (2007) Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 145:1426-38
57. Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, Buccheister A, Hu J, Latif Z, Tselis A, Lisak R (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11:646-51
58. Kimelberg HK, Nedergaard M (2010) Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics 7:338-53
59. Koch M, Mostert J, Heersema D, De Keyser J (2007a) Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci 255:35-41
60. Koch M, Mostert J, Heersema D, Teelken A, De Keyser J (2007b) Plasma S100beta and NSE levels and progression in multiple sclerosis. J Neurol Sci 252:154-8
61. Kukley M, Capetillo-Zarate E, Dietrich D (2007) Vesicular glutamate release from axons in white matter. Nat Neurosci 10:311-20
62. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705-12
63. Kuzhikandathil EV, Molloy GR (1994) Transcription of the brain creatine kinase gene in glial cells is modulated by cyclic AMP-dependent protein kinase. J Neurosci Res 39:70-82
64. Kuzhikandathil EV, Molloy GR (1999) Proximal promoter of the rat brain creatine kinase gene lacks a consensus CRE element but is essential for the cAMP-mediated increased transcription in glioblastoma cells. J Neurosci Res 56:371-85
65. Langemann H, Kabiersch A, Newcombe J (1992) Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 32:248-52
66. Lassmann H, Reindl M, Rauschka H, Berger J, Aboul-Enein F, Berger T, Zurbriggen A, Lutterotti A, Bruck W, Weber JR, Ullrich R, Schmidbauer M, Jellinger K, Vandevelde M (2003) A new paraclinical CSF marker for hypoxialike tissue damage in multiple sclerosis lesions. Brain 126:1347-57
67. Lazzarino G, Amorini AM, Eikelenboom MJ, Killestein J, Belli A, Di Pietro V, Tavazzi B, Barkhof F, Polman CH, Uitdehaag BM, Petzold A (2010) Cerebrospinal fluid ATP metabolites in multiple sclerosis. Mult Scler 16:549-54
68. Leary SM, Davie CA, Parker GJ, Stevenson VL, Wang L, Barker GJ, Miller DH, Thompson AJ (1999) 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 246:1023-6
69. Lee MA, Blamire AM, Pendlebury S, Ho KH, Mills KR, Styles P, Palace J, Matthews PM (2000) Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 57:65-70
70. Lovatt D, Sonnewald U, Waagepetersen HS, Schousboe A, He W, Lin JH, Han X, Takano T, Wang S, Sim FJ, Goldman SA, Nedergaard M (2007) The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex. J Neurosci 27:12255-66
71. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, Lassmann H, Turnbull DM (2009) Mitochondrial changes within axons in multiple sclerosis. Brain 132:1161-74
72. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, Atkins HL, Azzarelli B, Kolar OJ, Bruck W (2007) Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130: 1254-62
73. Minderhoud JM, Mooyaart EL, Kamman RL, Teelken AW, Hoogstraten MC, Vencken LM, Gravenmade EJ, van den Burg W (1992) In vivo phosphorus magnetic resonance spectroscopy in multiple sclerosis. Arch Neurol 49: 161-5
74. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81: 89-131
75. Mostert JP, Sijens PE, Oudkerk M, De Keyser J (2006) Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci Lett 402:22-4
76. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D, Arnason BGW, Antel JP, Arnold DL (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248:979-86
77. Nave KA (2010) Myelination and the trophic support of long axons. Nat Rev Neurosci 11:275-83
78. Ouardouz M, Coderre E, Basak A, Chen A, Zamponi GW, Hameed S, Rehak R, Yin X, Trapp BD, Stys PK (2009a) Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol 65:151-9
79. Ouardouz M, Coderre E, Zamponi GW, Hameed S, Yin X, Trapp BD, Stys PK (2009b) Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Ann Neurol 65:160-6
80. Parry A, Corkill R, Blamire AM, Palace J, Narayanan S, Arnold D, Styles P, Matthews PM (2003) Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 250:171-8
81. Patel TB, Clark JB (1979) Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 184:539-46
82. Raine CS (1984) On the association between perinodal astrocytic processes and the node of Ranvier in the C.N.S. J Neurocytol 13:21-7
83. Ramsaransing GS, De Keyser J (2006) Benign course in multiple sclerosis: a review. Acta Neurol Scand 113:359-69
84. Ransom B, Behar T, Nedergaard M (2003) New roles for astrocytes (stars at last). Trends Neurosci 26:520-2
85. Reichenbach A, Derouiche A, Kirchhoff F (2010) Morphology and dynamics of perisynaptic glia. Brain Res Rev 63:11-25
86. Rose EM, Koo JC, Antflick JE, Ahmed SM, Angers S, Hampson DR (2009) Glutamate transporter coupling to Na,K-ATPase. J Neurosci 29:8143-55
87. Salter MG, Fern R (2005) NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438:1167-71
88. Sarchielli P, Greco L, Floridi A, Gallai V (2003) Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 60:1082-8
89. Seehusen F, Baumgartner W (2010) Axonal pathology and loss precede demyelination and accompany chronic lesions in a spontaneously occurring animal model of multiple sclerosis. Brain Pathol 20:551-9
90. Silver IA, Erecinska M (1997) Energetic demands of the Na +K+ ATPase in mammalian astrocytes. Glia 21:35-45
91. Sonnewald U, Westergaard N, Schousboe A (1997) Glutamate transport and metabolism in astrocytes. Glia 21:56-63
92. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D (2005) Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128:1016-25
93. Stanimirovic DB, Ball R, Small DL, Muruganandam A (1999) Developmental regulation of glutamate transporters and glutamine synthetase activity in astrocyte cultures differentiated in vitro. Int J Dev Neurosci 17:173-84
94. Steen C, Wilczak N, Hoogduin JM, Koch M, De Keyser J (2010) Reduced creatine kinase B activity in multiple sclerosis normal appearing white matter. PLoS One 5: e10811
95. Stys PK (2005) General mechanisms of axonal damage and its prevention. J Neurol Sci 233:3-13
96. Su KG, Banker G, Bourdette D, Forte M (2009) Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 9:411-7
97. Tachikawa M, Fukaya M, Terasaki T, Ohtsuki S, Watanabe M (2004) Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci 20:144-60
98. Tekkok SB, Brown AM, Westenbroek R, Pellerin L, Ransom BR (2005) Transfer of glycogen-derived lactate from astrocytes to axons via specific monocarboxylate transporters supports mouse optic nerve activity. J Neurosci Res 81:644-52
99. Thompson RJ, Kynoch PA, Sarjant J (1980) Immunohistochemical localization of creatine kinase-BB isoenzyme to astrocytes in human brain. Brain Res 201:423-6
100. Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, McLean MA, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH (2006) Metabolite changes in early relapsingremitting multiple sclerosis. A two year follow-up study. J Neurol 253:224-30
101. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-85
102. Trapp BD, Stys PK (2009) Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 8:280-91
103. Vallejo-Illarramendi A, Domercq M, Perez-Cerda F, Ravid R, Matute C (2006) Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 21:154-64
104. van der Knaap MS, Pouwels PJW (2005) Magnetic resonance spectroscopy: basic principles and application in white matter disorders. In: Magnetic resonance of myelination and myelin disorders (van der Knaap MS, Valk J, eds). Berlin: Springer, 859-80
105. Vandevelde M, Zurbriggen A (2005) Demyelination in canine distemper virus infection: a review. Acta Neuropathol 109:56-68
106. Wender R, Brown AM, Fern R, Swanson RA, Farrell K, Ransom BR (2000) Astrocytic glycogen influences axon function and survival during glucose deprivation in central white matter. J Neurosci 20:6804-10
107. Wilkins A, Scolding N (2008) Protecting axons in multiple sclerosis. Mult Scler 14:1013-25
108. Witte ME, Bo L, Rodenburg RJ, Belien JA, Musters R, Hazes T, Wintjes LT, Smeitink JA, Geurts JJ, De Vries HE, van der Valk P, van Horssen J (2009) Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 219:193-204
109. Wolosker H, Panizzutti R, Engelender S (1996) Inhibition of creatine kinase by S-nitrosoglutathione. FEBS Lett 392: 274-6
110. Xu GY, Liu S, Hughes MG, McAdoo DJ (2008) Glutamateinduced losses of oligodendrocytes and neurons and activation of caspase-3 in the rat spinal cord. Neuroscience 153:1034-47
111. Yudkoff M, Nelson D, Daikhin Y, Erecinska M (1994) Tricarboxylic acid cycle in rat brain synaptosomes. Fluxes and interactions with aspartate aminotransferase and malate/aspartate shuttle. J Biol Chem 269:27414-20
112. Zeinstra E, Wilczak N, De Keyser J (2000) [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neurosci Lett 289:75-7
113. Zhang X, Peng L, Chen Y, Hertz L (1993) Stimulation of glycogenolysis in astrocytes by fluoxetine, an antidepressant acting like 5-HT. Neuroreport 4:1235-8
114. Ziskin JL, Nishiyama A, Rubio M, Fukaya M, Bergles DE (2007) Vesicular release of glutamate from unmyelinated axons in white matter. Nat Neurosci 10:321-30